Targeting RIG-I with 5'ppp-modified RNA for immunotherapy of hepatocellular carcinoma (HCC)
L Posselt, I Lazic, A Funk, S Kirchleitner, S Schievenbusch, T Adunka, S Endres, P Düwell, S Rothenfusser, M Schnurr · Zeitschrift für Gastroenterologie · 2014 · Heft 09
Bibliografische Angaben
Zusammenfassung
Background: HCC is the most common primary malignant type of liver cancer. Median survival for patients with advanced tumors is less than one year. Novel treatment options are urgently needed. The cytosolic helicase retinoic acid-inducible gene I (RIG-I) is an immune receptor for viral 5'-triphosphat-RNA (ppp-RNA) and its activation leads to innate and adaptive immunity via type I IFN and proinflammatory cytokines. In addition, it promotes the intrinsic pathway of apoptosis in tumor cells. This project focuses on the development of 5'ppp-RNAs targeting RIG-I for HCC therapy. Methods: A synthetic 5'ppp-RNA was ge…
